ArticleCureus2024
A Comparison of Intrathecal Dexmedetomidine and Fentanyl as Adjuvants to 0.5% Hyperbaric Levobupivacaine for Lower Abdominal Surgeries: A Prospective, Double-Blinded, Randomized Controlled Trial.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Due to its affordability and ease of application, the subarachnoid block is the most frequently used method for lower abdominal procedures. Levobupivacaine has an onset of sensory and motor blockade comparable to that of bupivacaine and prolongs the duration of analgesia while facilitating quick recovery from motor block. Fentanyl and dexmedetomidine, when used as additives to intrathecal local anesthetic, can extend the duration of sensory and motor blockade and enhance postoperative analgesia. Aims and objectives The purpose of this study is to examine and compare the effectiveness of fentanyl and dexmedetomidine administered as adjuvants to 0.5% hyperbaric levobupivacaine intrathecally in lower abdominal operations with respect to block characteristics, postoperative analgesia as measured by visual analog scale (VAS) scores, hemodynamic changes, and adverse effects. Materials and methods Seventy patients were randomized into two groups of 36 each. Group LF received 15mg of 0.5% hyperbaric levobupivacaine with 25mcg of fentanyl, and Group LD received 15mg of 0.5% hyperbaric levobupivacaine with 10mcg of dexmedetomidine intrathecally. Results Patients in Group LD had a significantly longer duration of sensory and motor block than those in Group LF. In Group LF, the onset of sensory and motor blockade was faster (6.25 ± 1.89 minutes and 9.00 ± 3.24 minutes) compared to Group LD (8.70 ± 1.93 minutes and 10.95 ± 4.03 minutes). The length of sensory and motor blockade in Group LD was longer than in Group LF (308.28 ± 6.36 minutes vs. 232.28 ± 7.01 minutes and 198.20 ± 6.52 minutes vs. 157.45 ± 6.30 minutes, respectively). The total postoperative requirement for analgesics in the initial 24 hours, and the mean VAS scores were lower in Group LD. Conclusion Patients in Group LD experienced a significantly longer duration of sensory and motor block than those in Group LF. The onset of sensory and motor blockade was significantly faster in Group LF than in Group LD. The total postoperative requirement for analgesics in the initial 24 hours and the mean VAS scores were lower in Group LD. This concludes that the use of dexmedetomidine as an adjuvant to 0.5% hyperbaric levobupivacaine during the subarachnoid block provides prolonged postoperative analgesia, reduces total analgesic requirements, and maintains stable hemodynamics, while the use of fentanyl as an adjuvant to hyperbaric levobupivacaine enhances the onset of both sensory and motor blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.